首页> 美国卫生研究院文献>Wiley-Blackwell Online Open >Use of a small molecule cell cycle inhibitor to control cell growth and improve specific productivity and product quality of recombinant proteins in CHO cell cultures
【2h】

Use of a small molecule cell cycle inhibitor to control cell growth and improve specific productivity and product quality of recombinant proteins in CHO cell cultures

机译:使用小分子细胞周期抑制剂来控制细胞生长并提高CHO细胞培养物中重组蛋白的比生产率和产品质量

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The continued need to improve therapeutic recombinant protein productivity has led to ongoing assessment of appropriate strategies in the biopharmaceutical industry to establish robust processes with optimized critical variables, that is, viable cell density (VCD) and specific productivity (product per cell, qP). Even though high VCD is a positive factor for titer, uncontrolled proliferation beyond a certain cell mass is also undesirable. To enable efficient process development to achieve consistent and predictable growth arrest while maintaining VCD, as well as improving qP, without negative impacts on product quality from clone to clone, we identified an approach that directly targets the cell cycle G1-checkpoint by selectively inhibiting the function of cyclin dependent kinases (CDK) 4/6 with a small molecule compound. Results from studies on multiple recombinant Chinese hamster ovary (CHO) cell lines demonstrate that the selective inhibitor can mediate a complete and sustained G0/G1 arrest without impacting G2/M phase. Cell proliferation is consistently and rapidly controlled in all recombinant cell lines at one concentration of this inhibitor throughout the production processes with specific productivities increased up to 110 pg/cell/day. Additionally, the product quality attributes of the mAb, with regard to high molecular weight (HMW) and glycan profile, are not negatively impacted. In fact, high mannose is decreased after treatment, which is in contrast to other established growth control methods such as reducing culture temperature. Microarray analysis showed major differences in expression of regulatory genes of the glycosylation and cell cycle signaling pathways between these different growth control methods. Overall, our observations showed that cell cycle arrest by directly targeting CDK4/6 using selective inhibitor compound can be utilized consistently and rapidly to optimize process parameters, such as cell growth, qP, and glycosylation profile in recombinant antibody production cultures.
机译:对提高治疗性重组蛋白生产率的持续需求导致了对生物制药行业中适当策略的持续评估,以建立具有优化关键变量(即活细胞密度(VCD)和比生产率(每细胞产品,qP))的稳健过程。即使高VCD是滴度的积极因素,但超过一定细胞量的不受控制的增殖也是不希望的。为了使有效的工艺开发能够在保持VCD的同时实现一致且可预测的生长停滞并改善qP,而又不影响克隆之间的产品质量,我们确定了一种方法,该方法可通过选择性地抑制细胞周期G1检查点直接靶向小分子化合物对细胞周期蛋白依赖性激酶(CDK)4/6的功能对多个重组中国仓鼠卵巢(CHO)细胞系的研究结果表明,选择性抑制剂可以介导完整和持续的G0 / G1阻滞而不影响G2 / M期。在整个生产过程中,在一种抑制剂浓度下,所有重组细胞系中的细胞增殖都可以持续,迅速地得到控制,比生产率提高到110µpg /细胞/天。另外,就高分子量(HMW)和聚糖谱而言,mAb的产品质量属性不会受到负面影响。实际上,高甘露糖在处理后会降低,这与其他成熟的生长控制方法(例如降低培养温度)相反。微阵列分析显示了这些不同的生长控制方法之间的糖基化调控基因表达和细胞周期信号通路的主要差异。总体而言,我们的观察结果表明,使用选择性抑制剂化合物直接靶向CDK4 / 6可以阻止细胞周期停滞,并且可以持续快速地用于优化过程参数,例如重组抗体生产培养物中的细胞生长,qP和糖基化过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号